Vitiligo

The novel topical skincare treatment Total Eye was effective in treating periorbital wrinkles, dryness, laxity, and dark circles in patients 35-65 years old.

With this decision, ruxolitinib cream has become the first treatment approved by the FDA for the repigmentation of skin in vitiligo.

In the study, 77% of patients treated with the Cal/BD foam treatment were satisfied with its effectiveness, 60% were satisfied with its ease of use, and 73.9% were satisfied in terms of global satisfaction.

Dr. Cohen speaks on combining sun protective measures, such as sunscreen, protective clothing, and antioxidant supplements.

Dr. Lal speaks to how different cultures and different geographical locations can influence UV protection methods, and how sunless tanners can be used to avoid overexposure to UV light outdoors or in tanning beds.

Dr. Craiglow speaks on the public perception of UV safety, how people can best avoid sunburn, and her own personal experience with melanoma and non-melanoma skin cancers.

The authors unanimously agreed that doctors should explain the potential benefits and negatives of the treatment and all centers should have a phototherapy protocol in place to address episodes of symptomatic erythema and other adverse events.

Dr. Harold Edington gives an overview of Australia's public health campaign regarding UV safety, as well as the lessons Americans can take away from these measures.

Drs. Pandya and King discuss patient’s visit and how providers can help set expectations about the disease course.

Dr. Woolery-Lloyd shares her approach to talking to patients about vitiligo.

Drs Woolery-Lloyd, King and Pandya share how vitiligo affects patients’ quality of life.

Drs Rosmarin, King, and Pandya give an overview of clinical presentation and classification of vitiligo.

Though a majority of the study population could not identify the condition, certain groups- such as Arab-speaking participants- had a basic knowledge of and positive attitude toward vitiligo.

Investigators suggest that health care providers have a “unique opportunity” to facilitate shared decision making and empower patients and caregivers by involving them in the practice of eczema care.

Drs Pandya discusses vitiligo pathophysiology, the role of genetic and environmental factors, and how to communicate with patients about it.

A vitiligo expert, Dr Amit Pandya, provides an overview of vitiligo.

Patients who reported spending 11 or more hours a week tending to their AD had a greater disease burden and frequent changes in mood.

A significant increased incidence of FFA has been recorded in recent years, prompting investigators to study the implications of the disease on health-related quality of life.

New data suggest a combination of cosmetic and psychiatric care for patients with the chronic pigmentation condition may provide multi-systemic benefit.

Dr. Craiglow speaks on how dermatologists can set expectations with their patients regarding the effectiveness and timeliness of current vitiligo therapies,

Dr. Karan Lal speaks on treating vitiligo in patients from across the world, and how he expects a wave of prescription requests for ruxolitinib cream following the potential FDA approval.

Dr. Cohen of Yale details new therapeutic strategies and the different cultural perspectives regarding vitiligo.

An updated review highlights both the efficacy and safety of the increasingly popular vitiligo treatment.

Many patients with vitiligo have become disillusioned with healthcare due to a lack of long-term, effective management strategies. However, Dr. Chovatiya believes the impending ruxolitinib cream approval may signal real change in the treatment of the skin disorder.